Phase II study of 3-deazauridine in advanced colorectal adenocarcinoma.

Abstract

A phase II study of 3-deazauridine (DAUR) showed poor activity in previously treated patients with advanced colorectal adenocarcinoma. There were no responses among 15 patients treated on a dose schedule of 1200 mg/m2/day for 5 days repeated at 3-week intervals. Toxicity included mild nausea and vomiting, occasional mucositis, diarrhea, and dizziness. A minimal degree of myelosuppression was observed.

• Authors: S Bruno, P J Creaven, E Ledesma, D Poster, J Yoon, A Mittelman
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 5 Issue 1 Pg. 69-71 (Feb 1982) ISSN: 0277-3732 [Print] United States
• PMID: 7081140 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• 3-Deazauridine
• Uridine

Topics

• 3-Deazauridine (administration & dosage, adverse effects)
• Adenocarcinoma (drug therapy)
• Adult
• Aged
• Antineoplastic Agents (administration & dosage, adverse effects)
• Colonic Neoplasms (drug therapy)
• Digestive System (drug effects)
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Rectal Neoplasms (drug therapy)
• Uridine (analogs & derivatives)